פתוביולוגיה מולקולארית של גיסט

1. Mazur MT, Clark HB. 1983. Gastric stromal tumors. Reappraisal of histogenesis. Am.
J. Surg. Pathol. 7:507–19
2. Isozaki K, Hirota S, Nakama A, Miyagawa J, Shinomura Y, et al. 1995. Disturbed intestinal
movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in
Ws/Ws mutant rats. Gastroenterology 109:456–64
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. 1998. Gain-of-function
mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–80
4. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. 1998. Gastrointestinal
pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic
characteristics of the interstitial cells of Cajal. Am. J. Pathol. 152:1259–69
5. Miettinen M, Lasota J. 2005. KIT (CD117): a review on expression in normal and
neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem.
Mol. Morphol. 13:205–20
6. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, et al. 2004. Protein kinaseCθ is highly
expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
Clin. Cancer Res. 10:4089–95
www.annualreviews.org • Molecular Pathobiology of GIST 577
Annu. Rev. Pathol. Mech. Dis. 2008.3:557-586. Downloaded from www.annualreviews.org
by Ben Gurion University Library on 05/12/12. For personal use only.
7. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, et al. 2004. Protein kinase
C θ (PKCθ) expression and constitutive activation in gastrointestinal stromal tumors
(GISTs). Cancer Res. 64:5127–31
8. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. 2005. PKC θ, a
novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially
useful for identifying KIT-negative tumors. Pathol. Int. 55:106–12
9. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, et al. 2004. The novel marker,
DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT
or PDGFRA mutation status. Am. J. Pathol. 165:107–13
10. Corless CL, Fletcher JA, Heinrich MC. 2004. Biology of gastrointestinal stromal tumors.
J. Clin. Oncol. 22:3813–25
11. Miettinen M, Lasota J. 2003. Gastrointestinal stromal tumors (GISTs): definition, occurrence,
pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. 54:3–24
12. Herawi M, Montgomery EA, Epstein JI. 2006. Gastrointestinal stromal tumors (GISTs)
on prostate needle biopsy: a clinicopathologic study of 8 cases. Am. J. Surg. Pathol.
30:1389–95
13. Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP.
2006. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal
masses: a diagnostic pitfall. Int. J. Gynecol. Pathol. 25:288–92
14. Miettinen M, Sobin LH. 2001. Gastrointestinal stromal tumors in the appendix: a clinicopathologic
and immunohistochemical study of four cases. Am. J. Surg. Pathol. 25:1433–37
15. Ortiz-Hidalgo C, de Leon B, Albores-Saavedra J. 2000. Stromal tumor of the gallbladder
with phenotype of interstitial cells of Cajal: a previously unrecognized neoplasm. Am. J
Surg. Pathol. 24:1420–23
16. Hamberg P, de Jong FA, Boonstra JG, van DJ, Verweij J, Sleijfer S. 2006. Non-islet-cell
tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor
possibly worsened by imatinib. J. Clin. Oncol. 24:e30–31
17. Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, et al. 2006. Gastrointestinal
stromal tumors in a cohort of Chinese patients in Hong Kong. World J. Gastroenterol.
12:2223–28
18. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn
PC. 2005. Incidence of gastrointestinal stromal tumours is underestimated: results of a
nation-wide study. Eur. J. Cancer 41:2868–72
19. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, et al. 2005. Gastrointestinal
stromal tumors: the incidence, prevalence, clinical course, and prognostication
in the preimatinib mesylate era. Cancer 103:821–29
20. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. 2005. Gastrointestinal stromal
tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence
and pathologic risk stratification study. Int. J. Cancer 117:289–93
21. Tzen CY, Wang JH, Huang YJ, Wang MN, Lin PC, et al. 2007. Incidence of gastrointestinal
stromal tumor: a retrospective study based on immunohistochemical and
mutational analyses. Dig. Dis. Sci. 52:792–97
22. Tran T, Davila JA, El-Serag HB. 2005. The epidemiology of malignant gastrointestinal
stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am. J. Gastroenterol.
100:162–68
23. Miettinen M, Sobin LH, Lasota J. 2005. Gastrointestinal stromal tumors of the stomach:
a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases
with long-term follow-up. Am. J. Surg. Pathol. 29:52–68
24. Miettinen M, Makhlouf H, Sobin LH, Lasota J. 2006. Gastrointestinal stromal tumors
of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular
genetic study of 906 cases before imatinib with long-term follow-up. Am. J. Surg. Pathol.
30:477–89
25. Agaimy A,Wuensch PH. 2005. Gastrointestinal stromal tumours in patients with othertype
cancer: a mere coincidence or an etiological association? A study of 97 GIST cases.
Z. Gastroenterol. 43:1025–30
26. O’riain C, Corless CL, Heinrich MC, Keegan D, Vioreanu M, et al. 2005. Gastrointestinal
stromal tumors: insights from a new familial GIST kindred with unusual genetic
and pathologic features. Am. J. Surg. Pathol. 29:1680–83
27. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. 2003. Kinase
mutations and imatinib response in patients with metastatic gastrointestinal stromal
tumor. J. Clin. Oncol. 21:4342–49
28. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, et al. 2005. Acquired resistance
to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Clin. Cancer Res. 11:4182–90
29. Heinrich MC, Griffith DJ, Druker BJ,Wait CL, Ott KA, Zigler AJ. 2000. Inhibition of
c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood 96:925–32
30. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, et al. 2001. STI571 inactivation
of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical
implications. Oncogene 20:5054–58
31. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, et al. 2005. A knockin
mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res.
65:6631–39
32. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, et al. 2003. Gastrointestinal
stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine
kinase. Proc. Natl. Acad. Sci. USA 100:6706–11
33. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, et al. 2001. KIT activation is a
ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:8118–21
34. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, et al. 2004. Mechanisms
of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors
(GISTs). Oncogene 23:3999–4006
35. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, et al. 2006. Oncogenic Kit signaling and
therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc. Natl.
Acad. Sci. USA 103:12843–48
36. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, et al. 2006. Phosphoproteomic
analysis of AML cell lines identifies leukemic oncogenes. Leuk. Res. 30:1097–
104
37. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. 2001. Regulation
of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia
15:1923–31
38. Agosti V, Corbacioglu S, Ehlers I,Waskow C, Sommer G, et al. 2004. Critical role for
Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development.
J. Exp. Med. 199:867–78
39. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, et al. 2000. Point mutation
in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis
and oogenesis without affecting other kit responses. EMBO J. 19:1312–26
www.annualreviews.org • Molecular Pathobiology of GIST 579
Annu. Rev. Pathol. Mech. Dis. 2008.3:557-586. Downloaded from www.annualreviews.org
by Ben Gurion University Library on 05/12/12. For personal use only.
40. Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, et al. 2001.
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells
by the D816V c-Kit mutant. Blood 98:1365–73
41. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. 2004. Structural basis
for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem.
279:31655–63
42. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, et al. 2003. Structure of a c-kit product
complex reveals the basis for kinase transactivation. J. Biol. Chem. 278:31461–64
43. Foster R, Griffith R, Ferrao P, Ashman L. 2004. Molecular basis of the constitutive
activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
J. Mol. Graph. Model. 23:139–52
44. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. 2007. Neoplasia driven by mutant
c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell
Biol. 27:267–82
45. Liu H, Chen X, Focia PJ, He X. 2007. Structural basis for stem cell factor-KIT signaling
and activation of class III receptor tyrosine kinases. EMBO J. 26:891–901
46. Bauer S, Yu LK, Demetri GD, Fletcher JA. 2006. Heat shock protein 90 inhibition in
imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 66:9153–61
47. Fumo G, Akin C, Metcalfe DD, Neckers L. 2004. 17-Allylamino-17-
demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively
activated KIT protein in human mast cells. Blood 103:1078–84
48. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R,Wardelmann E. 2005. PDGFRα- and
c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive
histological and immunohistochemical features. Histopathology 46:166–75
49. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. 2003. PDGFRA
activating mutations in gastrointestinal stromal tumors. Science 299:708–10
50. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, et al. 2003. Gain-of-function
mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal
tumors. Gastroenterology 125:660–67
51. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, et al. 2004. Differential
expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of
gastrointestinal stromal tumors depends predominantly on the tumor site. Mod. Pathol.
17:889–94
52. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, et al. 2005. Correlation of KIT and
platelet-derived growth factor receptor α mutations with gene activation and expression
profiles in gastrointestinal stromal tumors. Oncogene 24:1066–74
53. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, et al. 2004. PDGFRA
germline mutation in a family with multiple cases of gastrointestinal stromal tumor.
Gastroenterology 126:318–21
54. de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, et al. 2006. Intestinal
neurofibromatosis is a subtype of familial GIST and results from a dominant activating
mutation in PDGFRA. Gastroenterology 131:1907–12
55. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. 2007. The plateletderived
growth factor receptor α is destabilized by geldanamycins in cancer cells. J. Biol.
Chem. 282:445–53
56. Debiec-Rychter M, Wasag B, Stul M, De WI, Van Oosterom A, et al. 2004. Gastrointestinal
stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
J. Pathol. 202:430–38
57. Medeiros F, Corless CL, Duensing A, Hornick JL, OliveiraAM,et al. 2004.KIT-negative
gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J.
Surg. Pathol. 28:889–94
58. Sakurai S, Hasegawa T, Sakuma Y,Takazawa Y, Motegi A, et al. 2004. Myxoid epithelioid
gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST
with mutations of platelet-derived growth factor receptor α gene. Hum. Pathol. 35:1223–
30
59. Tzen CY, Mau BL. 2005. Analysis of CD117-negative gastrointestinal stromal tumors.
World J. Gastroenterol. 11:1052–55
60. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, et al. 2004.
Association of platelet-derived growth factor receptor α mutations with gastric primary
site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J. Mol.
Diagn. 6:197–204
61. Wozniak A, Sciot R, Guillou L, Pauwels P,Wasag B, et al. 2007. Array CGH analysis in
primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site
and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer
46:261–76
62. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, et al. 2004. Gene expression
in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic
site. Clin. Cancer Res. 10:3282–90
63. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, et al. 2004. Gastrointestinal
stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression
profiles. Oncogene 23:7780–90
64. Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, et al. 2001. Germline
mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal
stromal tumors and urticaria pigmentosa. Cancer 92:657–62
65. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, et al. 2002. Familial gastrointestinal
stromal tumors associated with dysphagia and novel type germline mutation
of KIT gene. Gastroenterology 122:1493–99
66. Isozaki K, Terris B, Belghiti J, Schiffman S, Hirota S, Vanderwinden J-M. 2000.
Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal
stromal tumors. Am. J. Pathol. 157:1581–85
67. Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, et al. 2007. Multiple gastrointestinal
stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am. J. Surg. Pathol.
31:224–32
68. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, et al. 2001. Familial gastrointestinal
stromal tumor with hyperpigmentation: association with a germline mutation of
the c-kit gene. Gastroenterology 120:210–15
69. Nishida T, Hirota S,Taniguchi M, Hashimoto K, Isozaki K, et al. 1998. Familial gastrointestinal
stromal tumours with germline mutation of the KIT gene. Nat. Genet. 19:323–24
70. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, et al. 2005. Gastrointestinal
stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic
study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. 27:179–87
71. Carney JA. 1999. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal
paraganglioma (Carney Triad): natural history, adrenocortical component, and possible
familial occurrence. Mayo Clin. Proc. 74:543–52
72. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG.
2005. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic,
and genotypic characteristics. Am. J. Surg. Pathol. 29:1170–76
73. Maertens O, Prenen H, Debiec-Rychter M,Wozniak A, Sciot R, et al. 2006. Molecular
pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum. Mol.
Genet. 15:1015–23
74. Miettinen M, Fetsch JF, Sobin LH, Lasota J. 2006. Gastrointestinal stromal tumors in
patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45
cases. Am. J. Surg. Pathol. 30:90–96
75. Stewart DR, Corless CL, Rubin BP, Heinrich MC, Messiaen LM, et al. 2007. Mitotic recombination
as evidence of alternative pathogenesis of gastrointestinal stromal tumours
in neurofibromatosis type 1. J. Med. Genet. 44:e61
76. Agaimy A,Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, et al. 2007. Minute gastric
sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show
c-KIT mutations. Am. J. Surg. Pathol. 31:113–20
77. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. 2002. KIT mutations are
common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am.
J. Pathol. 160:1567–72
78. Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, et al. 2006. High incidence
of microscopic gastrointestinal stromal tumors in the stomach. Hum. Pathol. 37:1527–35
79. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O’Leary TJ. 1998. KIT
mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors.
Lab. Invest. 78:1633–36
80. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. 1999. Mutations in exon 11 of
c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors
and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154:53–60
81. Li SQ, O’Leary TJ, Sobin LH, Erozan YS, Rosenthal DL, Przygodzki RM. 2000. Analysis
of KIT mutation and protein expression in fine needle aspirates of gastrointestinal
stromal/smooth muscle tumors. Acta Cytolog. 44:981–86
82. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, et al. 2002. Prognostic value of
KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal
tumors. J. Clin. Oncol. 20:3898–905
83. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, et al. 1999. Effect of c-kit mutation
on prognosis of gastrointestinal stromal tumors. Cancer Res. 59:4297–300
84. Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, et al. 2006.
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor
prognosis. Gastroenterology 130:1573–81
85. Cho S, Kitadai Y, Yoshida S, Tanaka S, Yoshihara M, et al. 2006. Deletion of the KIT
gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal
stromal tumor in the stomach. Int. J. Oncol. 28:1361–67
86. Liu XH, Bai CG, Xie Q, Feng F, Xu ZY, Ma DL. 2005. Prognostic value of KIT mutation
in gastrointestinal stromal tumors. World J. Gastroenterol. 11:3948–52
87. Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA, et al. 2005.
Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in
patients with completely resected gastrointestinal stromal tumors: a study by the Spanish
Group for Sarcoma Research (GEIS). J. Clin. Oncol. 23:6190–98
88. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, et al. 2003. Deletion of Trp-557
and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with
metastatic behavior of gastrointestinal stromal tumors. Int. J Cancer 106:887–95
89. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. 2004. A great majority
of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant
potential. Lab. Invest. 84:874–83
90. Lasota J, Stachura J, Miettinen M. 2006. GISTs with PDGFRA exon 14 mutations
represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab.
Invest. 86:94–100
91. Gold JS, van der Zwan SM, Gonen M, Maki RG, Singer S, et al. 2007. Outcome of
metastatic GIST in the era before tyrosine kinase inhibitors. Ann. Surg. Oncol. 14:134–
42
92. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, et al. 2003.
Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the
duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of
167 cases. Am. J. Surg. Pathol. 27:625–41
93. Bergmann F, Gunawan B, Hermanns B, Hoer J, Schumpelick V, Fuzesi L. 1998. Cytogenetic
and morphologic characteristics of gastrointestinal stromal tumors. Recurrent
rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common
anomalies. Verh. Dtsch. Ges. Pathol. 82:275–78
94. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M. 2001. Chromosomal
aberrations in malignant gastrointestinal stromal tumors: correlation with c-
KIT gene mutation. Cancer Genet. Cytogenet. 128:24–30
95. Fukasawa T, Chong JM, Sakurai S, Koshiishi N, Ikeno R, et al. 2000. Allelic loss of 14q
and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in
gastrointestinal stromal tumor. Jpn. J. Cancer Res. 91:1241–49
96. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. 2002. Biology and genetic aspects of
gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol.
33:484–95
97. Kim NG, Kim JJ, Ahn JY, Seong CM, Noh SH, et al. 2000. Putative chromosomal
deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal
tumors. Int. J. Cancer 85:633–38
98. el-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. 2000. Highresolution
deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal
tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer 27:387–91
99. Gunawan B, von HA, Sander B, Schulten HJ, Haller F, et al. 2007. An oncogenetic
tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of
cytogenetic evolution with prognostic implications. J. Pathol. 211:463–70
100. El Rifai W, Sarlomo-Rikala M, Miettinen M, Knuutila S, Andersson LC. 1996. DNA
copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors.
Cancer Res. 56:3230–33
101. O’ Leary T, Ernst S, Przygodzki R, Emory T, Sobin L. 1999. Loss of heterozygosity
at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab.
Invest. 79:1461–67
102. Schurr P, Wolter S, Kaifi J, Reichelt U, Kleinhans H, et al. 2006. Microsatellite DNA
alterations of gastrointestinal stromal tumors are predictive for outcome. Clin. Cancer
Res. 12:5151–57
103. el-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. 2000. DNA
sequence copy number changes in gastrointestinal stromal tumors: tumor progression
and prognostic significance. Cancer Res. 60:3899–903
104. el-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. 2000. Highresolution
deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal
tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer 27:387–91
105. Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, et al. 2003. High prognostic
value of p16INK4 alterations in gastrointestinal stromal tumors. J. Clin. Oncol.
21:1688–97
106. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, et al. 2005. 9p21
locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and
platelet-derived growth factor receptor α gene alterations. Cancer 104:159–69
107. Ricci R, Arena V, Castri F, Martini M, Maggiano N, et al. 2004. Role of p16/INK4a in
gastrointestinal stromal tumor progression. Am. J. Clin. Pathol. 122:35–43
108. Sabah M, Cummins R, Leader M, Kay E. 2004. Loss of heterozygosity of chromosome 9p
and loss of p16INK4A expression are associated with malignant gastrointestinal stromal
tumors. Mod. Pathol. 17:1364–71
109. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, et al. 2005. Loss of p16 protein
defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray
study. Clin. Cancer Res. 11:638–45
110. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, et al. 2005. Prognostic significance
of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor
and the relevance of the risk grade. Hum. Pathol. 36:828–37
111. Pruneri G, Mazzarol G, Fabris S, Del CB, Bertolini F, et al. 2003. Cyclin D3 immunoreactivity
in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification
and is associated with nuclear p27 accumulation. Mod. Pathol. 16:886–92
112. Nemoto Y, Mikami T, Hana K, Kikuchi S, Kobayashi N, et al. 2006. Correlation of
enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach:
relevance of cellularity and p27kip1. Pathol. Int. 56:724–31
113. Tornillo L, Duchini G, Carafa V, Lugli A, Dirnhofer S, et al. 2005. Patterns of gene
amplification in gastrointestinal stromal tumors (GIST). Lab. Invest. 85:921–31
114. Feakins RM. 2005. The expression of p53 and bcl-2 in gastrointestinal stromal tumours
is associated with anatomical site, and p53 expression is associated with grade and clinical
outcome. Histopathology 46:270–79
115. Panizo-Santos A, Sola I, Vega F, De Alava E, Lozano MD, et al. 2000. Predicting
metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle
regulatory proteins. Int. J. Surg. Pathol. 8:133–44
116. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, et al. 2001.
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal
stromal tumor. N. Engl. J. Med. 1052:1052–56
117. Debiec-Rychter M, Sciot R, Le CA, Schlemmer M, Hohenberger P, et al. 2006. KIT
mutations and dose selection for imatinib in patients with advanced gastrointestinal
stromal tumours. Eur. J. Cancer 42:1093–103
118. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, et al. 2005. PDGFRA
mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity
to imatinib. J. Clin. Oncol. 23:5357–64
119. Weisberg E,Wright RD, Jiang J, Ray A, Moreno D, et al. 2006. Effects of PKC412, nilotinib,
and imatinib against GIST-associated PDGFRA mutants with differential imatinib
sensitivity. Gastroenterology 131:1734–42
120. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, et al. 2006. Molecular
correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol.
24:4764–74
121. Van den Abbeele AD, Badawi RD. 2002. Use of positron emission tomography in oncology
and its potential role to assess response to imatinib mesylate therapy in gastrointestinal
stromal tumors (GISTs). Eur. J. Cancer 38(Suppl. 5):S60–S65
122. Choi H, Charnsangavej C, de Castro FS, Tamm EP, Benjamin RS, et al. 2004. CT
evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate
treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol.
183:1619–28
123. Sharma SV, Gajowniczek P,Way IP, Lee DY, Jiang J, et al. 2006. A common signaling
cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes.
Cancer Cell 10:425–35
124. Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, et al. 2007. Histone H2AX is
a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with
imatinib mesylate. Cancer Res. 67:2685–92
125. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, et al. 2007. Pathologic and
molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal
tumors. Clin. Cancer Res. 13:170–81
126. Bickenbach K,Wilcox R, Veerapong J, Kindler HL, Posner MC, et al. 2007. A review of
resistance patterns and phenotypic changes in gastrointestinal stromal tumors following
imatinib mesylate therapy. J. Gastrointest. Surg. 11:758–66
127. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, et al. 2005. Acquired resistance
to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Clin. Cancer Res. 11:4182–90
128. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, et al. 2004. A missense mutation
in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal
tumors. Cancer Res. 64:5913–19
129. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, et al. 2005. Mechanisms of
resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the
PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128:270–79
130. Grimpen F, Yip D, McArthur G, Waring P, Goldstein D, et al. 2005. Resistance to
imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal
stromal tumour. Lancet Oncol. 6:724–27
131. Koyama T, Nimura H, Kobayashi K, Marushima H, Odaira H, et al. 2006. Recurrent
gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation
after imatinib treatment. Gastric Cancer 9:235–39
132. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. 2004. Late resistance
to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a
second KIT mutation. Br. J. Cancer 90:2059–61
133. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, et al. 2005. Acquired
resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT
mutations. Lancet Oncol. 6:249–51
134. Loughrey MB,Waring PM, Dobrovic A, Demetri G, Kovalenko S, McArthur G. 2006.
Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase
inhibitors. Clin. Cancer Res. 12:6205–6
135. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, et al. 2006.
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal
tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12:1743–49
136. Heinrich M, Maki G, Corless C, Antonescu CR, Fletcher J, et al. 2006. 2006 ASCO
Annu. Meet. Proc. 24(18S):520S (Abstr.)
136a. Heinrich MC, Corless CL, Liegl B, Fletcher CD, Raut CP, et al. 2007. 2007 ASCO
Annu. Meet. Proc. 25(18S):10006 (Abstr.)
137. Miettinen M, Lasota J. 2006. Gastrointestinal stromal tumors: pathology and prognosis
at different sites. Semin. Diagn. Pathol. 23:70–83
138. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, et al. 2004. Use of c-
KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients
with advanced gastrointestinal stromal tumours entered on phase I and II studies of the
EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40:689–95
139. Heinrich M, Shoemaker JS, Corless C, Hollis D, Demetri G, et al. 2005. 2005 ASCO
Annu. Meeting Proc. 23(16s):3s (Abstr.)